

## QIBA Amyloid → Tau Profile Transition: Exploratory Meeting 3

Friday, September 9, 2022, at 9 am CT

### Call Summary

#### In attendance

Dawn Matthews, MS, MBA

Tobey James Betthausen, PhD, MS

Charlie Chen

Bradley T. Christian, PhD

Alexander Drzezga, MD

Rachid Fahmi, MSc, PhD

Peter Ngum, MSc

Nancy Obuchowski, PhD

David Scott, PhD

Anne Smith, PhD

Richard Wahl, MD

Dean F. Wong, MD, PhD

Yibao Wu, PhD

#### RSNA Staff

Joe Koudelik

Julie Lisiecki

**Moderator:** Ms. Matthews

#### The following topics were discussed: (further information below)

- Update on NM committee vote and scheduled presentation to Steering Committee
- Dropbox reference library
- One-page reference pamphlet and harmonization interactions
- Slides for the QIBA Steering Committee mtg. on Sept. 15<sup>th</sup>
- Profile starter kit update
- Test-retest and longitudinal data
- Systematic approach to developing Profile contents and harmonizing
- PET Tau and Profile opportunity timeline

#### [NM Committee Vote Outcome and Next Step](#)

- The NM Coordinating Committee ballot closed on Wednesday, September 7<sup>th</sup> with a majority (**10 votes**) in favor with **0** “no” votes and **1** abstention. (14 members)
- The next step is to present the case for the new biomarker committee (BC) at the September 15<sup>th</sup> Steering Committee call.
- This will be followed by a Steering Committee vote to consider approval the BC, soon after.

#### **Further detail regarding the above items:**

- PET Tau group members were asked to provide any feedback regarding the slides to be presented by September 12<sup>th</sup> to [Ms. Matthews](#)
- Consensus was that a Tau Profile was needed due to FDA approval of the Flortaucipir tracer.
  - After 2024 would be too late.
- Significant overlap with the Amyloid Profile will help streamline Tau Profile writing
- CMS reimbursement may be possible when PET Tau is used in diagnosis
- A Profile could help with numerous controllable technical factors and aid with decreasing variability
- Aim of the Profile will be to quantify image acquisition variability and harmonize with various tracers
- Significant test-retest and longitudinal data are available

#### [Suggested task forces by focus area \(to work offline, independently of staff support\)](#)

- Meningeal uptake: Dr. Wong
- Head motion: Dr. Fahmi
- SUVR vs DVR: Dr. Lammertsma (was volunteered by others) and Dr. Wong
- Dynamic Modeling
- Time window of acquisition
- Reconstruction parameters

- PET/CT vs. PET/MR
- the issue regarding 3R vs 4R
- PSP (binding)
- PI-2620
- basal ganglia uptake
- peripheral cortical uptake
- RSNA staff can create a Google sign up form for task forces once topics are finalized / agreed upon

#### PET Amyloid Publication Update

- The PET Amyloid manuscript has been accepted for publication by [the Journal of Nuclear Medicine \(JNM\)](#) and will have good prominence once published

#### Action items:

- Dr. Wong to send a paper to Ms. Matthews for inclusion on the Dropbox
- Ms. Matthews to circulate the e-flyer and slides for feedback
- RSNA Staff to create a Google sign-up form for task forces once focus areas are finalized

**Next Call:** TBD {most likely will be Friday, Oct 14<sup>th</sup> at 9 am CT}

---

Parties interested in joining the [QIBA LinkedIn](#) page for QIBA updates should visit: <https://www.linkedin.com/company/rsna-qiba>

**Reference:** [Ms. Matthews' slides](#) (07.15.2022)